[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367307-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367307-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","network-pharmacology-and-ai-in-cancer-research-uncovering-biomarkers-and-therapeutic-targets-for-ralgds-mutations","Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations","","Target therapies remain limited for many cancer types, driving high mortality. This study uses AI-guided network pharmacology to identify selective biomarkers and diagnostic/therapeutic strategies for KRAS-associated genes, centered on RALGDS mutations. Genomic, epidemiology, proteomics network interactions, and multi-omics enrichment were integrated with structured E-pharmacophore modeling, eraser-based binding cavity capture, and lead compound design. Binding stability was validated via 100 ns molecular dynamics and MMGBSA, while pathway and interaction analyses highlighted KRAS-driven MAPK/RAS signaling and RALGDS as a key protein.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/network-pharmacology-and-ai-in-cancer-research-uncovering-biomarkers-and-therapeutic-targets-for-ralgds-mutations/367307/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/network-pharmacology-and-ai-in-cancer-research-uncovering-biomarkers-and-therapeutic-targets-for-ralgds-mutations/367307.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the study?","Question",{"text":63,"@type":64},"To use AI and network pharmacology to identify selective biomarkers and develop diagnostic and therapeutic strategies for KRAS-associated genes focused on RALGDS mutations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which data sources were integrated to support biomarker and target discovery?",{"text":68,"@type":64},"Genomic data, cancer epidemiology, proteomics network interactions, and multi-omics enrichment were analyzed together to guide modeling and target identification.",{"name":70,"@type":61,"acceptedAnswer":71},"How was the designed selective lead validated for KRAS binding?",{"text":72,"@type":64},"The selective molecule was assessed for binding cavity fit and stability using 100 ns molecular dynamics simulations and MMGBSA, confirming a well-configured binding profile and stabilizing interactions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367307,1791393649,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nNetwork pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations  \nS. Mohammed Zaidh1,2, Hariharan Thirumalai Vengateswaran1, Mohammad Habeeb1, Kiran Balasaheb Aher3, Girija Balasaheb Bhavar4, N. Irfan1􀀍 & K N V Chenchu Lakshmi5  \nThe lack of target therapies is accountable for the higher mortality of various types of cancer. To address this issue, we selected a target mutated Kirsten rat sarcoma virus oncogene homologue, which plays a significant role in various cancers. Our study aims to identify selective biomarkers and develop diagnostic and therapeutic strategies for KRAS-associated genes using artificial intelligence. Initially, Genomic data, cancer epidemiology, proteomics network interactions, and omics enrichment were analyzed. Structured E-pharmacophore model aided in capturing the binding cavity using eraser algorithms and fabricating a new selective lead compound forthe KRSA. The selective molecule was abridged inside the binding cavity and stability was validated through 100 ns molecular dynamics simulations. Epidemiological-neural network studies indicated KRAS mutations leads 40 types of cancer, exclusively pancreatic and colorectal cancers, with diploid and missense mutations as primary factors. Pathway analysis highlighted the involvement of the MAPK and RAS signaling pathways in cancer development and proteomics analysis identified RALGDS as a key protein. Protein-based pharmacophore analysis mapped the biologically active features such as donor, acceptor and aromatic ring with the designed ligands. The results of interaction interpretation illustrate that the amino acid Tyr566 formed an H-bond interaction with the amine group of the octyl ring system and 20 amino acids crafted to properly orient the molecule to fit inside the polar cavity of KRAS protein. The MMGBSA score of − 53.33 kcal/mol conformed to the well-configured binding with KRSA and realistic model simulation exposed the π–π, π–cationic and hydrophobic interactions stabilised the molecule inside the KRSA protein throughout 100 ns simulation. The study demonstrates the vitality of AI and network pharmacology to identify potential-target biomarkers for KRAS-associated genes, paving the way for improved cancer diagnostics and therapeutics.  \nKeywords KRAS–RALGDS, Genomics statistics, Pathway analysis, Multi-omics, Molecular modelling  \nThe most often mutated oncogene (Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS)) is responsible for a diversity of malignancies, such as NSCLC-non-small-cell lung cancer1, PDAC-pancreatic ductaladenocarcinoma,& CRC-colorectal cancer2–6. The discovery of certain inhibitors and the recognition of driver genes have completely changed the way that cancer is treated, greatly increasing progression-free survival and lowering toxicity in targeted therapy7–10. One of the extremely aggressive and severe diseases is pancreatic cancer which has a poor prognosis and limited available treatments. Mutations in the KRAS oncogene are a key factor among the many genetic changes linked to the onset and spread of pancreatic cancer. Roughly 90% of individuals with pancreatic cancer have KRAS mutations, which are among the most frequent genetic abnormalities discovered in these patients11–14. Targeted therapies for other mutations, like EGFR and ALK gene fusion, have advanced; however, KRAS has proven to be a difficult disease to treat, with few effective treatments available until sotorasib for the KRAS (G12C) subtype was recently approved15. Because of its inherent qualities, targeting KRAS has  \n1Crescent School of Pharmacy, BS Abdur Rahman Crescent Institute of Science and Technology, Chennai 600048, India. 2D3 DrugTech Lab Pvt Ltd, Chennai 600048, India. 3Department of Pharmaceutical Quality Assurance, ShriVile Parle Kelavani Mandal’s Institute of Pharmacy, Dhule, Maharashtra 424001, India. 4Departmen","cbCaibRs53HK5MA2","https://ap.wps.com/l/cbCaibRs53HK5MA2","pdf",2360551,13,"English","# Introduction\n## Target therapy challenge and study aim\n## Data integration for biomarker discovery\n# Methods and modeling\n## E-pharmacophore modeling and lead design\n## Molecular dynamics and MMGBSA validation\n# Results\n## Epidemiological-neural network findings\n## Pathway and proteomics identification\n## Interaction mapping and binding interpretation\n# Conclusion\n## Implications for cancer diagnostics and therapeutics","[{\"question\":\"What is the main objective of the study?\",\"answer\":\"To use AI and network pharmacology to identify selective biomarkers and develop diagnostic and therapeutic strategies for KRAS-associated genes focused on RALGDS mutations.\"},{\"question\":\"Which data sources were integrated to support biomarker and target discovery?\",\"answer\":\"Genomic data, cancer epidemiology, proteomics network interactions, and multi-omics enrichment were analyzed together to guide modeling and target identification.\"},{\"question\":\"How was the designed selective lead validated for KRAS binding?\",\"answer\":\"The selective molecule was assessed for binding cavity fit and stability using 100 ns molecular dynamics simulations and MMGBSA, confirming a well-configured binding profile and stabilizing interactions.\"}]","Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations | PDF",1790170173,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8a670c887c7afcd7ae2c144282a2700.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fa2e63c935e511f6a64794c7dc15330.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12cf04997a1786d215385e247b75819f.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4e9d87be620074190b19014b298be37.webp",980,1287]